...agonist next quarter.May PDUFA date for Kadmon’s belumosudilFDA granted priority review to belumosudil (KD025) from Kadmon...
...NASDAQ:KDMN) to treat chronic graft-versus-host disease (GvHD). The ROCK2 inhibitor’s PDUFA date is May 30. In May, Kadmon...
...and 74%, respectively, in the pivotal Phase II open-label ROCKstar study for third-line chronic GvHD. Kadmon...

...as its first CMO.Palmer held a senior post at Shire plc, which Takeda acquired, and Kadmon...

...oral films containing apomorphine from Aquestive Therapeutics Inc. (NASDAQ:AQST). Kadmon’s GvHD therapy heading for FDA Kadmon...
...of motor neuron 1 telomeric SMN2 - Survival of motor neuron 2 centromeric Robin Sawka, BioCentury Staff Kadmon...

...gained $15.96 to $203.44 Thursday. Also raising capital on the back of positive data was Kadmon...
...after proposing the offering at a 5% discount to its close that day. On Monday, Kadmon...
...chronic graft-versus-host disease (see “Early Success in GvHD sets up NDA for Kadmon’s Lead” ). Kadmon’s...

...primary endpoint at an interim analysis of a pivotal trial for third-line chronic graft-versus-host disease, Kadmon...
...NDA next year for KD025 following next half's primary analysis. On a conference call Monday, Kadmon...
...Because the interim analysis covers all the trial's patients, the best ORR will not decrease. Kadmon...

...SVP of operations. He was VP of CMC at the Kadmon Pharmaceuticals LLC subsidiary of Kadmon...

...and free radical scavenger is approved in the U.S. The committee backed approval of Cufence trientine...
...edaravone (MCI-186, radicava) Syprine, trientine hydrochloride Emmaus Life Sciences Inc. Mitsubishi Tanabe Pharma Corp. Novartis AG Taiwan Liposome Co. Ltd. Cufence trientine...

...Kadmon's close of $3.35 on June 11, before it proposed the offering after market hours. Kadmon's...
...chronic graft-versus-host disease (GvHD), idiopathic pulmonary fibrosis (IPF) and moderate to severe psoriasis. Next quarter, Kadmon...
...in the U.S. to treat chronic GvHD. Kadmon Holdings Inc. (NYSE:KDMN), New York, N.Y. Allison Johnson KD025, slx-2119 Kadmon...

...the xerostomia program has the same designation from FDA. MeiraGTx launched in 2015 out of Kadmon...